QIAGEN (QGEN) Q4 2025 earnings review
QIAGEN Exceeds 2025 Targets Despite Sharp Q4 Slowdown, Guides for H2 Rebound
QIAGEN beat its Q4 outlook with 1% CER sales growth (vs. 'steady' guidance) and $0.62 adjusted EPS (vs. ~$0.60). This capped a solid year where full-year sales grew 5% CER, hitting the high end of guidance. However, the 1% growth in Q4 marks a sharp deceleration from the 5-7% pace seen earlier in the year, with the PCR segment reversing into a 9% decline. Management points to macro challenges and the U.S. government shutdown as headwinds. The initial 2026 outlook calls for a rebound, with sales guided to grow at least 5% CER, implying a significant recovery in the second half of the year after a soft Q1.
🐂 Bull Case
The company exceeded its Q4 and full-year 2025 guidance for both sales and adjusted EPS, marking another quarter of solid execution despite a challenging macro environment.
Guidance for at least 5% CER sales growth and adjusted EPS of at least $2.50 CER in 2026 signals management's confidence in a second-half rebound, driven by new products and the end of headwinds from discontinued lines.
🐻 Bear Case
The slowdown from 5% CER growth in Q3 to just 1% in Q4 is significant. The weak Q1 2026 guidance for 1% CER growth suggests near-term headwinds are persisting.
Q4 adjusted operating margin compressed to 28.6% from 30.6% a year ago, hit by tariffs. The 2026 outlook bakes in 160 basis points of pressure from the Parse acquisition, tariffs, and currency, limiting near-term profit expansion.
⚖️ Verdict: ⚪
Neutral. QIAGEN continues to execute well, beating targets and laying the groundwork for future growth with the Parse acquisition. However, the sharp Q4 deceleration and soft Q1 guide are concerning. The investment case now hinges on a significant second-half 2026 recovery that is not yet guaranteed.
Key Themes
PCR Segment Reverses into Decline
The PCR / Nucleic Acid Amplification segment, a growth engine earlier in the year (+14% CER in Q1), has reversed course, declining 9% CER in Q4. Management attributes the weakness to the timing of OEM customer contracts and funding constraints. This shift from a key contributor to a significant laggard is a major red flag for underlying demand.
Strategic Entry into Single-Cell Analysis with Parse Acquisition
The December 2025 acquisition of Parse Biosciences marks a major strategic push into the high-growth single-cell analysis market. Parse's instrument-free, highly scalable 'Evercode' technology is a key differentiator. Management expects Parse to contribute ~$40M to 2026 sales and strengthen the Sample to Insight portfolio. While it will be dilutive to EPS by ~$0.04 in 2026, it represents a significant long-term growth driver.
Margin Discipline Offsets Headwinds
Despite 80 bps of pressure from tariffs and 40 bps from currency, QIAGEN expanded its full-year 2025 adjusted operating margin by 80 bps to 29.5%. This was driven by operational efficiencies. For 2026, the company expects to absorb another 160 bps of pressure (from Parse, tariffs, FX) to keep the margin steady, demonstrating strong underlying cost control.
Core Diagnostic Franchises Remain Solid
QIAGEN's key diagnostic growth pillars continued to perform. In Q4, QIAstat-Dx grew 15% CER, driven by demand for its syndromic testing panels. QuantiFERON grew 5% CER, impacted by tough comps from tenders in the prior year but still expanding. For the full year, these growth pillars delivered a combined 8% CER growth, hitting the company's $1.49 billion sales target.
Macro Environment Impacting Growth
Management cited macroeconomic challenges and the U.S. government shutdown for the Q4 slowdown. This pressure is expected to continue into early 2026, with Q1 guidance for sales growth of only 1% CER and a YoY decline in adjusted EPS to $0.54 CER. The recovery story is heavily weighted to the second half of the year.
Accounts Receivable Outpacing Sales
As of year-end 2025, accounts receivable stood at $402.6 million, a 15.3% increase from the prior year. This growth significantly outpaces the 6% increase in full-year reported sales. While not addressed by management, this could indicate more generous payment terms to secure sales or potential issues with collections, and warrants monitoring.
Other KPIs
Decelerating. Free cash flow declined 10% from $506M in FY 2024. The decrease reflects a 20% increase in capital expenditures, partly for a major ERP system upgrade, and $54M in cash payments for restructuring programs. While the cash generation remains healthy, the negative trend reflects a period of heavy investment.
The company continues a balanced capital allocation strategy. In addition to internal investments and closing two bolt-on acquisitions (Genoox and Parse), QIAGEN has returned over $1.1 billion to shareholders to date, ahead of its scheduled goal. In January 2026, it completed a $500 million synthetic share repurchase.
Guidance
Accelerating. This full-year target implies a significant re-acceleration from the 1% CER growth reported in Q4 2025 and guided for Q1 2026. The growth will be driven by new product launches and the end of headwinds from discontinued products in the second half of the year.
Accelerating. The midpoint implies growth of at least 4.2% from FY 2025's $2.40 CER. This demonstrates continued earnings growth despite absorbing significant margin pressure from the Parse acquisition and tariffs.
Stable. The outlook continues the decelerated growth rate seen in Q4, indicating that macro headwinds are persisting into the new year.
Reversing. This represents a decline from the $0.55 CER achieved in Q1 2025. Management explicitly attributes the drop to the dilutive impacts of the Parse acquisition and tariffs.
Key Questions
Confidence in H2 2026 Rebound
Given the 1% CER growth in Q4 2025 and guided for Q1 2026, what specific market improvements or product launch contributions give you confidence in the strong second-half acceleration required to meet the full-year guide of at least 5% growth?
PCR Segment Trajectory
The PCR segment reversed from +14% CER growth in Q1 to a 9% decline in Q4. How much of this is due to temporary factors like OEM contract timing versus a more structural slowdown in end-market demand?
Accounts Receivable Growth
Accounts receivable grew over 15% in 2025, more than double the rate of revenue growth. What is driving this dynamic, and does it reflect a change in customer payment behavior or collection cycles?